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RASSF1A is a key tumor-suppressor gene that is often
inactivated in a wide variety of solid tumors. Studies have
illustrated that RASSF1A plays vital roles in the
regulation of cell-cycle progression and functions as a
guardian of mitosis. Nevertheless, the precise mechanism
of RASSF1A-dependent regulation of mitosis remains
largely unclear. APC/C
Cdc20 is the master switch and
regulator of mitosis. The activity of APC/C
Cdc20 is tightly
controlled by phosphorylation and speciﬁc inhibitors to
ensure the sequential ubiquitination of downstream
targets. Here, we report on the novel ﬁnding of a
regulated circuitry that controls the timely expression
and hence activity of APC/C
Cdc20 during mitosis. Our
study showed that RASSF1A and APC/C
Cdc20 form a
molecular relay that regulates the APC/C
Cdc20 activity at
early mitosis. We found that RASSF1A inhibits APC/C
Cdc20
function through its D-box motifs. Paradoxically,
RASSF1A was also demonstrated to be ubiquitinated by
APC/C
Cdc20 in vitro and degraded at prometaphase despite
of active spindle checkpoint presence. The ﬁrst two unique
D-boxes at the N-terminal of RASSF1A served as speciﬁc
degron recognized by APC/C
Cdc20. Importantly, we found
that Aurora A and Aurora B directly phosphorylate
RASSF1A, a critical step by which RASSF1A switches
from being an inhibitor to a substrate of APC/C
Cdc20
during the course of mitotic progression. As a result of
RASSF1A degradation, APC/C
Cdc20 can then partially
activate the ubiquitination of Cyclin A in the presence of
spindle checkpoint. This circuitry is essential for the
timely degradation of Cyclin A. To conclude, our results
propose a new model for RASSF1A–APC/C
Cdc20 interac-
tion in ensuring the sequential progression of mitosis.
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Introduction
RASSF1A is a potent tumor suppressor that is known
to induce cell-cycle arrest. RASSF1A has been shown to
be a mitotic regulator and it regulates G2/M transition
by sequestering Cdc20 from APC/C, and hyperstabiliz-
ing the microtubules (Rong et al., 2004; Song et al.,
2004). Aurora A and B are mitotic kinases that regulate
the mitotic progression (Carmena et al., 2009). Recent
studies revealed that RASSF1A is a substrate of Aurora
A and the action of RASSF1A is regulated by Aurora A
phosphorylation (Rong et al., 2007; Song et al., 2009).
Particularly, Rong et al. (2007) showed that RASSF1A
can no longer hyperstabilize microtubules after being
phosphorylated by Aurora A. On the other hand, Song
et al. (2009) suggested that Aurora phosphorylation
induces RASSF1A-Cdc20 dissociation. However, the
precise mechanism of RASSF1A on G2/M regulation
remains elusive.
Anaphase-promoting complex/cyclosome (APC/C) is
a ubiquitin ligase that ubiquitinates mitotic proteins and
directs them to proteasomal degradation (Peters, 2006).
APC/C is sequentially activated by Cdc20 and Cdh1
during mitosis. In early mitosis, Cdc20 accumulates
and activates the catalytic activity of APC/C in the
ubiquitination of mitotic cyclins and securin via
recognition of D-box domain (King et al., 1996). Cdh1
later takes over from Cdc20 as the APC/C activator
from anaphase to G1 phase, and the APC/C
Cdh1 recruits
target substrates containing either D-box or KEN-box
(Pﬂeger and Kirschner, 2000).
The activity of APC/C is sequentially regulated.
During S phase and early mitosis, the activity of APC/
C
Cdc20 is regulated by Emi1 and mitotic checkpoint
complex at the spindle assembly checkpoint (SAC)
(Miller et al., 2006; Peters, 2006). Once all kinetochores
are attached to the mitotic spindle and the pulling force
is established, SAC is turned off and APC/C
Cdc20 is fully
activated to ubiquitinate securin. This leads to the
consequential activation of separase and the initiation of
anaphase (Pines, 2006).
It is suggested that APC/C
Cdc20 ubiquitinates its
substrate in a SAC-dependent or SAC-independent
manner. In the presence of SAC, APC/C
Cdc20 ubiquiti-
nates Cyclin A and NEK2A, but not Cyclin B and
Securin, despite that APC/C
Cdc20 recognized the D-boxes
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www.nature.com/oncof these proteins as degron (Geley et al., 2001; Hames
et al., 2001; Zur and Brandeis, 2001; Yamano et al.,
2004). This discrepancy can be explained by the
conformational change of substrate-recognition pocket
of APC/C
Cdc20 induced by SAC (Izawa and Pines, 2011).
APC/C
Cdc20-dependent ubiquitination is likely to be
controlled by multiple factors. It was shown that
binding between Cyclin A and Cks was essential for
the onset of SAC-independent degradation of Cyclin A
(Wolthuis et al., 2008). Importantly, expression of
nondegradable Cyclin A induced mitotic delay (Geley
et al., 2001; den Elzen and Pines, 2001). Degradation of
NEK2A is necessary for the re-establishment of inter-
centriolar linkage of the centrosome cycle (Hames et al.,
2001). These examples highlighted the importance of
degrading the mitotic proteins by APC/C on time during
mitotic progression.
Here, we discovered a regulatory mechanism by which
the expression of RASSF1A could be precisely con-
trolled during mitosis. Our ﬁndings provide explana-
tions for the physiological function of RASSF1A in the
timely entry and exit of mitotic cell division. We suggest
that RASSF1A acts as an inhibitor of APC/C
Cdc20
through its D-box domains at early mitosis, but
becomes a substrate of APC/C
Cdc20 as mitosis progresses.
This transformation was demonstrated to be controlled
through Aurora-dependent phosphorylation of RASS-
F1A. As mitosis progresses, the clearance of RASSF1A
inhibition leads to reactivation of APC/C
Cdc20, which
permits APC/C
Cdc20 to ubiquitinate Cyclin A, and
launches the subsequent course of mitosis to late
anaphase. This mechanism ensures a timely degradation
of Cyclin A and NEK2A during mitosis progression.
Results
RASSF1A is degradable by APC/C
Cdc20
Structural analysis revealed that RASSF1A protein has
six consensus D-boxes and one KEN-box (Figures 1a
and b). As both D-box and KEN-box are peptide
domains well recognized as APC/C degrons in directing
proteasomal degradation, it is plausible that RASSF1A
is a substrate of APC/C. We therefore determined
whether RASSF1A is degradable in APC/C-dependent
manner during mitosis. First, the protein level of
RASSF1A was traced in HeLa cells synchronized by
double thymidine block and release (Figure 2a). Our
result showed that RASSF1A degraded at 8h post-
thymidine release. Both ﬂuorescence-activated cell sort-
ing (FACS) analysis and degradation of Cyclin A
suggested that the HeLa cells entered G2/M phase at
8h post-thymidine release, concomitant to the activa-
tion of APC/C
Cdc20 (Geley et al., 2001). Next, we asked
whether the degradation of RASSF1A depends on
spindle checkpoint. To address this question, HeLa
cells synchronized by double thymidine block were
released into medium containing nocodazole to activate
the spindle checkpoint. Cell cycle was traced by
immunoblotting of Cyclin A and Cyclin B1 and FACS
analysis. As expected, Cyclin B1, Cdc20, Aurora A and
Aurora B accumulated with time following the release
from thymidine block (Figure 2b, left panels). The level
of RASSF1A remained steady for the ﬁrst 8h, after
which the protein level of RASSF1A and Cyclin A both
dropped with time. This phenomenon proceeded in-
dependent of the nocodazole-induced spindle arrest. To
determine the protein level of RASSF1A during mitotic
exit, mitotic HeLa cells were released into medium
without nocodazole. Progressive degradation of Cyclin
B1, Cdc20, Aurora A and Aurora B implied that cells
had completed anaphase and were en route for mitotic
exit (Figure 2b, right panel). The level of RASSF1A rose
after 4h post-nocodazole release when the lowest level
of Cdc20 was detected. Concomitantly, FACS analysis
showed that the cells entered G1 phase after 4h post-
nocodazole release. The data indicated that RASSF1A
was degraded during mitosis and accumulated at G1
phase. Taken together, we suggested that RASSF1A is a
putative substrate of APC/C and is degraded at early
mitosis.
The possible mechanisms behind the mitotic degrada-
tion of RASSF1A were then examined. There are two
activators of APC/C: Cdc20 and Cdh1. Using HeLa
cells transfected with Cdc20 or Cdh1 and synchronized
by double thymidine block, we determined whether both
Cdc20 and Cdh1-activated APC/C induced the degrada-
tion of RASSF1A. The protein level of RASSF1A was
analyzed by immunoblotting. Whereas overexpression
of the active mutant of Cdc20 (Cdc20(7A)) promoted
the premature downregulation of RASSF1A, Cdh1 did
not induce any effect on RASSF1A (Figure 2c). Con-
sistently, downregulation of RASSF1A was observed in
Cdc20-overexpressed HeLa cells but not in Cdh1-
overexpressed cells (Supplementary Figure 1). Further-
more, the Cdc20-dependent downregulation of RASS-
F1A was rescued by the treatment of proteasome
inhibitor MG-132 (Supplementary Figure 1). Cdc20
may induce RASSF1A degradation via proteasome. The
Cdc20-dependent degradation of RASSF1A was also
conﬁrmed in small interfering RNA (siRNA)-trans-
fected cells. HeLa cells were transfected with siRNA
targeting Cdc20 or Cdh1 and synchronized by double
thymidine block and release (Figure 2d). During mitosis,
RASSF1A was degraded in cells transfected with Cdh1
siRNA. This was similar to the cells transfected with
control siRNA. However, RASSF1A was stabilized in
cells transfected with Cdc20 siRNA. Our data thus
suggested that Cdc20 induced proteasome-dependent
degradation of RASSF1A at early mitosis.
Cdh1 and Cdc20 bind to the substrate of APC/C and
target them to ubiquitination (Pﬂeger and Kirschner,
2000; Yu, 2007). Thus, we further determined the
interaction between endogenous RASSF1A and Cdc20
by immunoprecipitation assay. We found that RASS-
F1A interacted with Cdc20 in mitotic HeLa cells and
mitotic HeLa cells treated with proteasome inhibitor
MG-132 (Figure 3a). On the contrary, our immunopre-
cipitation assay did not suggest any interaction between
Cdh1 and RASSF1A in asynchrony or mitosis. The
ﬁnding indicated that Cdc20 is capable of binding to
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OncogeneRASSF1A preferentially in mitotic cells. To deﬁne the
speciﬁc Cdc20-interacting domains on RASSF1A, im-
munoprecipitation was performed on cells co-trans-
fected with Cdc20 and deletion mutants of RASSF1A.
However, we found that both N-terminus and
C-terminus deletion constructs of RASSF1A main-
tained immunoprecipitating ability with Cdc20
(Figure 3b). As there are multiple D-boxes and a
KEN-box on RASSF1A, we performed motif mapping
assay to examine the interaction, if any, between these
speciﬁc RASSF1A domains and APC/C. Subsequent
constructs made with speciﬁc D-boxes (DBD) and
KEN-box (KD) deleted also did not seem to alter
the binding afﬁnity between RASSF1A and Cdc20
Figure 1 RASSF1A contains multiple D-boxes and KEN-box. (a) Alignment of RASSF1A and RASSF1C amino-acid sequences.
The putative D-boxes and KEN-box are highlighted in blue and red, respectively. The reported Aurora A phosphorylation site is
highlighted in pink. (b) Schematic diagram of multiple putative D-boxes and one KEN-box present on RASSF1A. The sequences of
the putative D-boxes and KEN-box are shown. * denotes every tenth amino acid in the amino acid sequence.
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Oncogene(Figure 3c). To further delineate the Cdc20-binding
domain on the N-terminus and C-terminus of RASS-
F1A, immunoprecipitation was done on cells co-
transfected with Cdc20 and truncated RASSF1A with-
out D-boxes and KEN-box (Figure 3d). Concurring
with Figure 3c, full-length RASSF1A
DBD1 6þKD bound
to Cdc20. However, the N-terminus of RASSF1A with
the D-boxes being deleted failed to bind to Cdc20
(1–140
DBDþKD). This interesting ﬁnding suggested that
the two D-boxes at the N-terminus of RASSF1A were
Cdc20-binding domains. It is concordant with the
hypothesis that Cdc20 targets D-boxes in recruiting
substrates to APC/C (Yu, 2007). Intriguingly, the
Cdc20-binding ability was retained in 1–264
DBDþKD
and 141–340
DBDþKD RASSF1A mutants. It is suggested
that there is D-box-independent Cdc20-binding domain
on the amino acids 141–264 of RASSF1A. Our ﬁndings
indicated that there are D-box-dependent and D-box-
independent Cdc20-interacting domains on RASSF1A.
RASSF1A inhibits APC/C
Cdc20 via D-boxes
RASSF1A was suggested to inhibit Cdc20 by sequester-
ing Cdc20 from APC/C previously (Song et al., 2004).
It seems to contradict with our present ﬁnding on the
APC/C
Cdc20 induction of RASSF1A degradation. In-
triguingly, we found that recombinant RASSF1A did
inhibit APC/C by in vitro APC/C inhibitory assay
(Figure 4a). The ﬁnding is in concordance with the
ﬁndings in previous reports (Song et al., 2004, 2008).
We further investigated the mechanism of RASSF1A-
mediated inhibition on APC/C
Cdc20 activity. As RASS-
F1A contains multiple D-boxes and a KEN-box, we
hypothesized that RASSF1A inhibits APC/C
Cdc20 via
D-boxes like APC/C pseudosubstrates Emi1 (Miller
et al., 2006). To determine the function of the D-boxes
and KEN-box on APC/C
Cdc20 inhibition, APC/C inhibi-
tory assay was performed using recombinant RASSF1A
with different D-boxes being deleted. Upon deletion of
any D-box cluster, RASSF1A could not inhibit APC/
C
Cdc20 effectively (Figure 4b). The ﬁnding conﬁrmed that
the D-boxes are critical for APC/C
Cdc20 inhibition.
Aurora-dependent phosphorylation of RASSF1A turns
RASSF1A from being an inhibitor to a substrate
of APC/C
Cdc20
Our results suggested that RASSF1A is both an
inhibitor and a substrate of APC/C
Cdc20. We then asked
how these two distinct functions of RASSF1A are
controlled. As this change in RASSF1A function occurs
at mitosis, we hypothesized that the inhibitor or
substrate property of RASSF1A is controlled by mitotic
kinase phosphorylation. Recent studies have reported
that RASSF1A is phosphorylated by Aurora A and B
(Rong et al., 2007; Song et al., 2009). In this study, we
also conﬁrmed their ﬁnding that T202 and S203 residues
of RASSF1A were the Aurora phosphorylation sites
(Supplementary Figure 2). Interestingly, Rong et al.
(2007) and Song et al. (2009) showed that phosphory-
lated form of RASSF1A failed to induce mitotic arrest.
Therefore, we postulated that Aurora phosphorylation
can change the role of RASSF1A from an inhibitor to
a substrate of APC/C
Cdc20. To address this hypothesis,
in vitro ubiquitination reaction was set up using
35S-labeled RASSF1A as substrate (Figure 5a). The
in vitro-translated RASSF1A was added to the ubiqui-
tination reaction containing mitotic APC/C (m-APC/C)
puriﬁed from mitotic HeLa cells in the presence or
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Figure 2 Cdc20 induces RASSF1A degradation. The protein level
of RASSF1A ﬂuctuates across the cell cycle progression. HeLa
cells were synchronized by double thymidine block followed by
releasing into medium without thymidine (a), double thymidine
block followed by releasing into nocodazole (b, left panel), or
nocodazole block and release (b, right panel). Cells collected at
indicated time points were analyzed by immunoblotting. Similar to
Cyclin A, RASSF1A was degraded at 8h after releasing from
thymidine block in the presence or absence of nocodazole.
(c) Ectopic expression of Cdc20 downregulates RASSF1A. HeLa
cells were transfected with vectors encoding FLAG-Cdc20(7A) or
FLAG-Cdh1 and synchronized by double thymidine block,
followed by releasing into nocodazole. The level of RASSF1A
at indicated time points were analyzed by immunoblotting.
(d) Knocking down of Cdc20 by siRNA stabilizes RASSF1A
during early mitosis. HeLa cells transfected with indicated siRNA
were synchronized and analyzed as in (c).
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Oncogeneabsence of Aurora A or Aurora B. The result showed
that RASSF1A was ubiquitinated by m-APC/C, and
strikingly, addition of Aurora A or Aurora B enhanced
the ubiquitination of RASSF1A by 7-fold and 14-fold,
respectively (Figure 5a, left panel). A control in vitro
ubiquitination experiment was set up in the presence of
Aurora A or Aurora B with or without the m-APC/C.
The result showed that the ubiquitinated form of
RASSF1A was absent in the control without m-APC/C
(Supplementary Figure 3). The data suggested that the
ubiquitination of RASSF1A was APC/C-dependent. To
conﬁrm the importance of the phosphorylation on the
ubiquitination of RASSF1A, we performed in vitro
ubiquitination reaction on wild-type, phospho-null and
phospho-mimic mutants of RASSF1A in the presence of
Aurora B. The wild-type RASSF1A (WT) and the
phospho-mimic RASSF1A (T202E/S203E) were readily
ubiquitinated by m-APC/C in the presence of Aurora B.
However, the phospho-null RASSF1A (T202A/S203A)
was resistant to ubiquitination (Figure 5a, right panel).
In addition, rather than RASSF1A
WT, phospho-mimic
RASSF1A was prone to ubiquitination by m-APC/C
without the supplement of Aurora B (Figure 5a, right
panel). These data suggested that Aurora kinase
phosphorylation of RASSF1A primes APC/C-depen-
dent ubiquitination on RASSF1A. To investigate the
Figure 3 RASSF1A interacts with Cdc20 during mitosis. (a) RASSF1A was immunoprecipitated from asynchronized (AS), mitotic
(M) or MG132-treated mitotic (MþMG132) HeLa cells as indicated. The immunoprecipitate and 2% of the input WCL was subjected
to immunoblotting (IP, immunoprecipitation; WCL, whole-cell lysate). (b) Cdc20 interacts with multiple domains on RASSF1A.
FLAG-Cdc20 and different fragments of HA-RASSF1A were co-transfected into HEK293 cells. The immunoprecipitate of FLAG-
cdc20 was analyzed by immunoblotting. (c) D-box and KEN-box of RASSF1A are dispensable for the interaction with Cdc20.
Different D-box deletion mutants of RASSF1A were co-transfected with FLAG-Cdc20 into HEK293 cells and the immunoprecipita-
tion–immunoblotting assay was performed as in (b). (d) Mapping of D-box-dependent and -independent Cdc20-binding domains
of RASSF1A. FLAG-Cdc20 and different fragments of HA-RASSF1A
DBDþKD were co-transfected into HEK293 cells and the
immunoprecipitation–immunoblotting assay was performed as in (b).
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Oncogenerole of Aurora-dependent phosphorylation of RASS-
F1A on its stability in vivo, we performed the in vivo
degradation assay of RASSF1A. For this assay, HeLa
cells transfected with WT HA-RASSF1A were treated
either with or without Aurora inhibitor (ZM447439
or 4-(40-Benzamidoanilino)-6,7-dimethoxyquinazoline
(AI-II)) for 2h (Mortlock et al., 2005; Heron et al.,
2006). Different mutants of HA-RASSF1A were ecto-
pically expressed in mitotic HeLa cells. The protein
translation of the cells was blocked by treatment of
cycloheximide and cells were collected at different time
points for immunoblotting (Figure 5b). The effect of the
Aurora inhibitors on Aurora kinases was conﬁrmed by
the reduction of phospho-Histone H3 (S-10) level
(Crosio et al., 2002). Agreeing with the result of
Figure 5a, WT and phospho-mimic (T202E/S203E)
RASSF1A was degraded rapidly. However, the phos-
pho-null (T202A/S203A) RASSF1A or RASSF1A in
cells pretreated with Aurora inhibitor was relatively
stable at the ﬁrst 60min after the treatment of
cycloheximide. Similar results were obtained from HeLa
cells co-transfected with HA-RASSF1A and Cdc20(7A)
(Supplementary Figure 4a). Together with the in vitro
ubiquitination assay, we clearly demonstrated that
Aurora-dependent phosphorylation was essential for
APC/C
Cdc20-mediated RASSF1A ubiquitination and
degradation.
As there are six D-boxes on RASSF1A, we further
examined which D-box is the degron recognized by
APC/C
Cdc20. The in vitro ubiquitination assay of
RASSF1A mutants was carried out in the presence of
m-APC/C and Aurora B. In our initial analysis, in vitro-
translated
35S-labeled single D-box deletion mutants of
RASSF1A (RASSF1A
DBD) were used as substrates.
Surprisingly, none of the single D-box mutants of
RASSF1A showed resistance to m-APC/C-dependent
ubiquitination (Figure 5c, left panel). We then generated
RASSF1A
DBD mutants with different combinations of
D-box deletion. The result showed that RASSF1A with
DB1 and DB2 deleted was resistant to m-APC/C-
dependent ubiquitination (Figure 5c, right panel). The
requirement of DB1 and DB2 for Cdc20-dependent
Figure 4 Inhibition of APC/C
Cdc20 by RASSF1A depends on the D-box clusters. (a) RASSF1A inhibits APC/C
Cdc20 in vitro.
Recombinant MBP-RASSF1A or MBP was added to the in vitro ubiquitination assay in the presence of Cdc20(WT) or Cdc20(7A).
The
35S-labeled N-terminal fragment of Cyclin B1 was used as the substrate (left panel). The amount of poly-ubiquitinated Cyclin B1
was quantiﬁed and the APC/C activities in each reaction relative to the control reaction containing Cdc20(7A) and MBP were
calculated (right panel). (b) Deletion of the D-box clusters abolishes the inhibitory effect of RASSF1A in vitro. In vitro APC/C
inhibitory assay was performed with recombinant RASSF1A
DBD mutants (left panel) and the activity of APC/C in the reaction was
determined (right panel). The loadings of different RASSF1A mutants were determined by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) and Coomassie Brilliant Blue (CBB) stain.
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Oncogenedegradation of RASSF1A was further conﬁrmed by
in vivo degradation assay. Different D-box-deleted
mutants of RASSF1A were transfected into HeLa cells
and the cells were arrested in mitosis. The degradation
of RASSF1A was chased by cycloheximide block
(Figure 5d). As expected, HA-RASSF1A
WT was de-
graded rapidly upon cycloheximide treatment. More-
over, HA-RASSF1A mutants without DB1 and DB2
stabilized HA-RASSF1A from Cdc20(7A)-dependent
degradation. Similar result was seen in HeLa cells
Figure 5 Aurora kinases facilitated the ubiquitination and degradation of RASSF1A. (a) Aurora kinases facilitated the
ubiquitination of RASSF1A by puriﬁed mitotic APC/C in vitro. The in vitro ubiquitination reaction was set up using APC/C
puriﬁed from mitotic HeLa cells. (Left panel)
35S-labeled RASSF1A was used as substrate. (Right panel)
35S-labeled wild-type or
phospho-mutants of RASSF1A were used as substrate. Where indicated, Aurora A or Aurora B was added. (b) Phosphorylation of
RASSF1A by Aurora kinases is essential for Cdc20-dependent degradation. HeLa cells were transfected with different mutants
of HA-RASSF1A. After 24h, cells were arrested to mitosis by nocodazole. Where indicated, cells were treated with 2mM ZM447439 or
2mM AI-II for 2h. The cells were then treated with 50mg/ml cycloheximide (CHX) and collected at indicated time points for
immunoblotting. (c) APC/C
Cdc20 ubiquitinates RASSF1A at DB1 and DB2 in vitro. Wild-type or mutated
35S-labeled RASSF1A was
subjected to in vitro ubiquitination assay using mitotic HeLa APC/C and puriﬁed Aurora B. RASSF1A was resistant to APC/C
ubiquitination when both DB1 and DB2 were deleted. (d) DB1 and DB2 of RASSF1A are essential for Cdc20-dependent degradation
in vivo. HeLa cells were transfected with different HA-RASSF1A mutants and treated as in (b). Consistent with in vitro ubiquitination
assay, RASSF1A
DBD1þ2 mutant was resistant to Cdc20-dependent degradation.
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Oncogeneco-transfected with different D-box-deleted mutants of
RASSF1A and FLAG-Cdc20(7A) (Supplementary
Figure 4b). The data provided clear evidence that DB1
and DB2 of RASSF1A serve as bona ﬁde degrons in the
APC/C
Cdc20-mediated degradation.
In our study, we demonstrated that RASSF1A was
ubiquitinated by APC/C
Cdc20 and the ubiquitination was
enhanced by Aurora-dependent phosphorylation. Then,
we further determined whether the interaction between
RASSF1A and Cdc20 is affected by Aurora phosphor-
ylation. In the report of Song et al. (2009), they
proposed that phospho-mimic mutant of RASSF1A
did not bind to Cdc20 and this allowed Cdc20 to
activate APC/C. However, our result indicated that
RASSF1A
WT, RASSF1A
T202A/S203A and RASSF1A
T203E/S203E
could immunoprecipitate with ectopically expressed
Cdc20 (Supplementary Figure 5a). In addition, we
demonstrated that both phospho-mimic and phospho-
null mutants of RASSF1A bind to endogenous APC/
C
Cdc20. Cdc20 or Cdc27 were immunoprecipitated from
the mitotic HeLa cells transfected with phospho-
mutants of RASSF1A. Our result indicated that both
endogenous Cdc20 and Cdc27 presented in the RASS-
F1A immunoprecipitates (Supplementary Figure 5b).
Furthermore, we determined the effect of Aurora
activity on the interaction between endogenous RASS-
F1A and Cdc20. Mitotic HeLa cells were treated with
MG132, Aurora inhibitor ZM447439 (ZM) or AI-II and
the interaction between endogenous RASSF1A and
Cdc20 was determined by immunoprecipitation
(Supplementary Figure 5c). The result showed that
RASSF1A could bind to Cdc20 regardless of the Aurora
activity. Then, we asked if the Aurora phosphorylation
is responsible for the binding between RASSF1A and
Cdc20 in a D-box-independent manner. To address
this question, the phospho-mutants of FL-RASS-
F1A
DBDþKD, RASSF1A
DBDþKD (1–264) and RASS-
F1A
DBDþKD (141–340) were generated by mutagenesis.
Different RASSF1A mutants and Cdc20 were co-
transfected into HeLa cells and the binding between
RASSF1A mutants and Cdc20 was determined by
immunoprecipitation (Supplementary Figure 5d). The
result illustrated that Cdc20 co-precipitated with
different mutants of RASSF1A irrespective to the
phosphorylation site mutation.
RASSF1A regulates APC/C activity and Cyclin A
degradation during mitosis
We showed that RASSF1A is an inhibitor of APC/C
and it becomes a substrate of APC/C
Cdc20 after
phosphorylating by Aurora kinase. The physiological
signiﬁcance of this regulatory circuit was then investi-
gated. It was shown that APC/C ubiquitinated its
substrates sequentially during mitosis (Peters, 2006).
As RASSF1A was degraded irrespective of spindle
checkpoint, we hypothesized that RASSF1A controls
the degradation of APC/C substrates before the onset of
spindle checkpoint. Similar to RASSF1A, Cyclin A and
Nek2A are degraded by APC/C irrespective of the
spindle checkpoint (Geley et al., 2001; Hames et al.,
2001; Hayes et al., 2006). Therefore, we determined
whether RASSF1A controls the degradation of Cyclin
A and Nek2A. RASSF1A was either overexpressed or
knocked down in HeLa cells. Cells were then synchro-
nized by double thymidine block and were released into
nocodazole. Immunoblottings revealed that the degra-
dation of Cyclin A was delayed in cells transfected with
RASSF1A or phospho-null RASSF1A compared with
control cells (Figure 6a and Supplementary Figure 6).
Degradation of Nek2A was also delayed in cells
transfected with RASSF1A (Figure 6a). On the other
hand, Cyclin B1 degradation was inhibited by the
activation of spindle checkpoint. This indicated that
RASSF1A regulates the time of Cyclin A and Nek2A
degradation during mitosis. However, the degradation
of Cyclin B was regulated by spindle checkpoint. HeLa
cells transfected with si-RASSF1A showed signiﬁcantly
less Cyclin A accumulation at early mitosis than control
siRNA (Figure 6b). Cyclin B1 also accumulated in cells
transfected with si-RASSF1A during the mitotic pro-
gression, despite the fact that the level of Cyclin B1
protein was initially lowered in RASSF1A knockdown
cells. This concurs with our ﬁnding that RASSF1A
inhibits the activity of APC/C. In addition, siRNA of
RASSF1A did not change the time of degradation of
Cyclin A and Nek2A. This suggested that there is
another level of regulation of APC/C or its substrates in
starting the degradation process (Peters, 2006; Pines,
2006; van Zon and Wolthuis, 2010).
As we showed that RASSF1A regulates the APC/C
via D-boxes, we next investigated the effect of RASS-
F1A
DBD mutants on the time of Cyclin A degradation. In
concordance with the result of in vitro inhibitory assay,
none of the RASSF1A
DBD mutant delayed the degrada-
tion of Cyclin A during mitosis (Figure 6c). This result
suggested that the D-boxes are important for RASSF1A
to function as an APC/C inhibitor.
Discussion
RASSF1A inhibits APC/C
Cdc20 activity at early mitosis
In this study, our data supported a role for RASSF1A
as an inhibitor of APC/C
Cdc20. In a previous study, Song
et al. (2004) suggested that RASSF1A could induce
G2/M arrest through inhibiting the APC/C activity by
sequestering Cdc20 after the dissociation of APC/C
Cdc20
from Emi1. Here, we further demonstrated that multiple
D-boxes in RASSF1A play an important role in
inhibiting APC/C
Cdc20 activity. Using in vitro APC/C
inhibitory assay, we showed that RASSF1A
WT was more
potent in inhibiting the APC/C
Cdc20 activity, whereas
D-box-deleted mutants of RASSF1A were less effective.
Also, although degradation of Cyclin A by APC/C
Cdc20
could be found in the presence of RASSF1A
WT, D-box-
deleted mutants did not exert an effect on the degrada-
tion of Cyclin A in synchronized HeLa cells during
mitosis. Particularly, our result suggested that the ﬁrst
two D-boxes (DB1 and DB2) of RASSF1A exert critical
effects on its inhibitory function. Among the RASSF1
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Oncogeneisoforms, only RASSF1A was shown to be a key tumor
suppressor involving in mitosis regulation (Rong et al.,
2004; Song et al., 2004). Different from other isoforms
such as RASSF1C at the N-terminal, the ﬁrst two
D-boxes of RASSF1A are speciﬁc to RASSF1A and are
not found in other isoforms. Our new ﬁnding provides
Figure 6 (a) RASSF1A delays Cyclin A degradation during mitosis. HeLa cells transfected with HA-RASSF1A were synchronized by
thymidine block and released into nocodazole. Cells were collected at indicated time points for immunoblotting (left panel). Cyclin A
and Nek2A were not degraded until 10h post-thymidine block in cells transfected with HA-RASSF1A, whereas it was degraded at 8h
in control cells. (b) RASSF1A promotes accumulation of Cyclin A. HeLa cells transfected with siRNA targeting RASSF1A were
synchronized and analyzed as in Figure 2b. The level of Cyclin A was consistently lower in cells transfected with RASSF1A siRNA
than those transfected with control siRNA throughout the assay. (c) D-box-deleted RASSF1A mutants fail to delay the degradation of
Cyclin A during mitosis. HeLa cells transfected with D-box-deleted mutants of RASSF1A were synchronized and analyzed as in (b).
The immunoblotting was performed (upper panel). Although RASSF1A
WT delayed the degradation of Cyclin A after the thymidine
block, none of the RASSF1A
DBD mutants delayed the degradation of Cyclin A. *Time point when Cyclin A degradation started.
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Oncogenean explanation in that APC/C
Cdc20 is preferentially
inhibited by RASSF1A. Intriguingly, deletion of the
D-boxes and KEN-box did not affect the binding
between RASSF1A and Cdc20. However,
RASSF1A
DBD1 6 failed to inhibit APC/C
Cdc20. This raised
the possibility that RASSF1A does not inhibit Cdc20 by
sequestration. Indeed, our data supported the notion
that RASSF1A might inhibit APC/C
Cdc20 as a pseudo-
substrate, similar to Mad3p, Acm1 and Emi1 (Miller
et al., 2006; Burton and Solomon, 2007; Enquist-
Newman et al., 2008). In the model of pseudosubstrate
inhibition of APC/C, the inhibitors present a D-box-like
structure but, for unknown mechanism, these pseudo-
substrates are not ubiquitinated by APC/C (Miller et al.,
2006; Burton and Solomon, 2007; Enquist-Newman
et al., 2008). Similarly, RASSF1A is not ubiquitinated
effectively by APC/C in vitro in the absence of Aurora
kinase. Thus, we believe that RASSF1A maintains as a
stable pseudosubstrate of APC/C at early mitosis.
Although an earlier report from Liu et al. (2007) did
not suggest an interaction between RASSF1A and
Cdc20, more recent investigations have highlighted
interaction between RASSF1A and Cdc20 (Wang
et al., 2008; Song et al., 2009). In this study, we found
that RASSF1A can bind to Cdc20 in a D-box-
dependent and D-box-independent manner. Speciﬁcally,
the ﬁrst two D-boxes at the N-terminus of RASSF1A
was shown to be Cdc20-binding domains. In addition, a
D-box-independent Cdc20-binding domain was mapped
to residues 141–264 of RASSF1A. Our study has
revealed an interesting binding strategy between RASS-
F1A and Cdc20
Phosphorylation by Aurora kinases turns RASSF1A from
an inhibitor to a speciﬁc substrate of APC/C
Cdc20
In this study, we demonstrated that Aurora kinases-
dependent phosphorylation triggers ubiquitination of
RASSF1A by APC/C
Cdc20. Whereas Aurora A is a well-
characterized oncoprotein that promotes mitotic pro-
gression, RASSF1A is a tumor suppressor that regulates
mitosis. The interplay between an oncoprotein and
tumor suppressor in mitosis can be shown in this
autoregulatory model. At the beginning of mitosis,
RASSF1A inhibits APC/C
Cdc20. Meanwhile, the accu-
mulation and activation of Aurora A and Aurora B,
during the course of mitosis progression, allow phos-
phorylation of RASSF1A that turn it into a substrate of
APC/C
Cdc20 (Figure 7). Additionally, RASSF1A was
shown to activate Aurora A (Liu et al., 2008). Thus,
RASSF1A may play a role in allowing the accumulation
and activation of Aurora A during mitosis, and this in
turn primes RASSF1A to degradation.
In this study, we presented data to support that
RASSF1A was ubiquitinated by APC/C
Cdc20 in mitosis.
Recent studies suggested that RASSF1A is ubiquiti-
nated by different E3 ligases. The study by Song et al.
(2008) showed that RASSF1A was degraded at S phase
in U2OS cell line, and the degradation of RASSF1A in S
phase was mediated by SCF
Skp2 complex. On the other
hand, Jiang et al. (2011) pinpointed that RASSF1A was
targeted by CUL4A-DDB1 complex during mitosis.
Taking together, these studies suggested that RASSF1A
is differentially regulated by ubiquitination in the
cell cycle.
It was proposed that Aurora A regulates RASSF1A
in mitosis by different mechanisms (Rong et al., 2007;
Song et al., 2009). In our model, we proposed that
Aurora A mediated Cdc20-dependent ubiquitination of
RASSF1A in mitosis. This released the RASSF1A-
dependent mitotic blockage. In addition, Song et al.
(2009) demonstrated that the expression of phospho-
mimetic RASSF1A in HeLa cell could overcome the
mitotic arrest caused by knocking down of Aurora A.
This implied that RASSF1A is a key substrate of
Aurora A in regulating the mitotic progression.
To our understanding, this is the ﬁrst report showing
that Aurora kinases enhanced the ubiquitination of
APC/C substrate. Our result raises an important
argument on whether phosphorylation controls the
ubiquitination of APC/C substrates. Previous reports
have shown that phosphorylation prevents the ubiqui-
tination of several APC/C substrates (Woodbury and
Morgan, 2007; Enquist-Newman et al., 2008). These
studies highlighted that phosphorylation may change
the conformation of substrates, which in turn hide the
D-box from Cdc20 or Cdh1. In the case of RASSF1A,
Aurora kinase-dependent phosphorylation may alter its
conformation, which allows APC/C
Cdc20 to ubiquitinate
RASSF1A.
In this study, DB1 and DB2 were demonstrated to be
the Cdc20-speciﬁc degrons on RASSF1A. As discussed
before, these two D-boxes are critical for the APC/C
inhibitory function of RASSF1A. Thus, DB1 and DB2
are the functional and autoregulatory domains on
RASSF1A; they are necessary for RASSF1A to be an
APC/C inhibitor, and they are also essential for the
degradation of RASS1A. Importantly, as the DB1 and
DB2 are speciﬁc for RASSF1A, the expression of
RASSF1A, not other RASSF1 isoforms, can be
speciﬁcally regulated during mitosis.
RASSF1A is a speciﬁc substrate of Cdc20 but not
Cdh1. Although several D-boxes are located at different
regions on RASSF1A, our data showed that RASSF1A
associates only with Cdc20. In addition to RASSF1A,
Acm1 and p21 were shown to be speciﬁc targets of APC/
C
Cdc20 (Hames et al., 2001; Amador et al., 2007; Enquist-
Newman et al., 2008). Study on Acm1 has suggested
that Cdc20 and Cdh1 can recognize D-box in different
ways (Enquist-Newman et al., 2008). The D-box at the
N-terminal of Acm1 is recognized by Cdc20 only.
However, the D-boxes at the middle region of Acm1
bind to Cdh1 at high afﬁnity. This implied that Cdc20
and Cdh1 recognize the substrates by different mechan-
isms. Therefore, further investigation on the Cdc20-
RASSF1A- and Cdc20-Acm1-binding mechanisms
may reveal important insights on APC/C
Cdc20-speciﬁc
interaction.
The activity of APC/C
Cdc20 is controlled by spindle
assembly checkpoint. Our results suggested that degra-
dation of RASSF1A by APC/C
Cdc20 can occur in the
presence of active spindle checkpoint. In fact, only few
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Oncogenesubstrates of APC/C
Cdc20, such as Cyclin A and Nek2A,
are ubiquitinated in the presence of spindle checkpoint.
Recently, Izawa and Pines (2011) demonstrated that
Cdc20 cooperates with APC8 to recruit substrate to
APC/C in the presence of spindle checkpoint. On the
other hand, when the spindle checkpoint is satisﬁed,
Cdc20 cooperates with APC8 and APC3 in recruiting
substrate to APC/C. This in turn changes the substrate
speciﬁcity so that APC/C
Cdc20 ubiquitinates different
substrates at different stages of mitosis(Izawa and Pines,
2011). Therefore, it is conceivable that RASSF1A is
recruited by Cdc20 and APC8 to APC/C for ubiquitination.
RASSF1A determines the timely degradation of Cyclin A
RASSF1A determines the time of degradation of
APC/C substrates in early mitosis. We demonstrated
that RASSF1A regulates the accumulation of Cyclin A
and NEK2A. By inhibiting the APC/C, RASSF1A
determines the time of degradation of Cyclin A and
NEK2A. Using Cyclin A as a model, we propose that
degradation of RASSF1A primes the partial activation
of APC/C regardless of the spindle checkpoint. The
partial activity of APC/C is critical in ubiquitination
and degradation of APC/C substrates such as Cyclin A.
This step is crucial for the initiation of anaphase
(Geley et al., 2001; den Elzen and Pines, 2001).
To conclude, we propose a model that supports
an autoregulatory mechanism for the APC/C
Cdc20
proteasomal activity (Figure 7). At the early mitosis,
APC/C
Cdc20 is inhibited by RASSF1A, whereas phos-
phorylation of RASSF1A by Aurora kinases turns
RASSF1A to a substrate of APC/C
Cdc20. Consequently,
APC/C
Cdc20 ubiquitinates RASSF1A. This results in the
partial activation of APC/C
Cdc20 that can further
ubiquitinate Cyclin A and NEK2A in the presence of
spindle checkpoint. After fulﬁlling the spindle check-
point, APC/C
Cdc20 further ubiquitinates its substrates
including Cyclin B1 and securin. This model provides
a new mechanism for the spatial degradation of
APC/C
Cdc20 substrates.
Materials and methods
Cell culture, cell cycle synchronization and drug treatments
HeLa cells and HEK293 cells were obtained from American
Type Culture Collection (Manassas, VA, USA) and were
maintained in Dulbecco’s modiﬁed Eagle’s medium containing
10% fetal bovine serum. HeLa cells are synchronized by
double thymidine block, thymidine–nocodazole block and
nocodazole block and release as described (Fang et al., 1998;
Petersen et al., 2000). To inhibit the proteasome in vivo, cells
were treated with 10mM MG-132 for 6h. To inhibit the Aurora
activity, cells were treated with 2mM ZM447439 (Tocris
Bioscience, Bristol, UK) or 2mM AI-II for 2h. To chase the
protein half-life in vivo, cells were incubated with 50mg/ml
cycloheximide for the indicated time points after 24h post
transfection. Unless speciﬁed, all the chemicals were purchased
from Calbiochem (Gibbstown, NJ, USA).
Plasmids and recombinant proteins
Coding sequence of Cyclin B1 (N-terminal 1–87), Aurora A,
Aurora B, Cdc20 and Cdh1 were ampliﬁed from HeLa cDNA
library by PCR. The open reading frame of RASSF1A was
ampliﬁed from pcDNA3.1-RASSF1A (a generous gift of R
Dammann, University of Heidelberg, Heidelberg, Germany).
All of the genes were cloned into pcDNA3.1 with N-terminal
(for Cdc20 and Cdh1) or C-terminal (for RASSF1A, Cyclin
B1, Aurora A and Aurora B) hemagglutinin (HA) or FLAG
tag. Site-directed mutagenesis was performed using Quik-
Figure 7 Model of RASSF1A regulation during mitosis. At the early mitosis, APC/C
Cdc20 is sequentially inhibited by Emi1 and
RASSF1A. RASSF1A is subsequently phosphorylated by Aurora A and Aurora B accumulating during mitosis. This phosphorylation
turns RASSF1A from an inhibitor to a substrate of APC/C
Cdc20. As a result, RASSF1A is ubiquitinated and targeted for proteasomal
degradation. Consequently, the partially activated APC/C
Cdc20 can ubiquitinate Cyclin A. The whole process occurs before passing the
spindle checkpoint.
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Oncogenechange site-directed mutagenesis (Stratagene, Santa Clara,
CA, USA). Expression vector encoding FLAG-Cdc20(7A)
mutant was described (Yudkovsky et al., 2000). To generate
MBP-RASSF1A, RASSF1A open reading frame was cloned
into pMAL-c2 vector (New England Biolabs, Ipswich, MA,
USA). MBP and MBP-RASSF1A was expressed in Escher-
ichia coli (BL21) and puriﬁed by amylose resin according to
standard procedures (New England Biolabs). The primer
sequences are available upon request.
Cell cycle analysis by ﬂow cytometry
Synchronized HeLa cells were collected at the indicated time
point for propidium iodide stain and FACS analysis (Amador
et al., 2007). HeLa cells ﬁxed with 70% ethanol were stained
with propidium iodide. All analyses were performed on a
FACSCalibur ﬂow cytometer and Cell Quest software (Becton
Dickinson, Franklin Lakes, NJ, USA).
siRNA and transfection
Plasmids or siRNAs were transfected into HeLa or HEK293
cells with Lipofectamine 2000 according to the manufacturer’s
recommendation (Invitrogen, Carlsbad, CA, USA). The siRNA
used in this study included Stealth RNAi targeting Cdc20
(50-AUGCGAAUGUGUCGAUCACUGGUGC-30) and Skp2
(50-AAGGGCUGAAAUGUUCAGCCAAUGG-30)( I n v i t r o g e n )
and siRNA targeting RASSF1A (50-dTdTGACCUCUGUGG
CGACUUCA-30) (Qiagen, Hilden, Germany). To determine
protein half-life, RASSF1A was co-transfected with
Cdc20(7A) in a 1:4 ratio. To transfect and to synchronize
cells at G1/S boundary, HeLa cells were transfected for 8h
after the ﬁrst thymidine block. Cells were then arrested by
thymidine again for 18h and released into fresh medium with
200ng/ml nocodazole.
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting was carried out as
previously described (Amador et al., 2007). The antibodies
used in this study included rabbit anti-HA (Abcam, UK),
anti-Cdc20 (Santa Cruz, Santa Cruz, CA, USA) anti-Aurora A
and anti-Aurora B (both from Epitomics, Burlingame, CA,
USA), anti-Histone H3 and anti-phospho-Histone H3 (Ser-10)
(both from Millipore, Billerica, MA, USA); mouse anti-FLAG
(Sigma, St Louis, MO, USA), anti-Cdh1 (Sigma), anti-Cdc27
(Sigma), anti-RASSF1A (Abcam), anti-Cyclin B1 (Abcam,
Cambridge, UK), anti-Skp2 (Invitrogen) and anti-Cyclin A
(Novocastra, Newcastle upon Tyne, UK); and goat anti-actin
(Santa Cruz). The band intensity of the immunoblot was
quantiﬁed by Quantity One software (Bio-Rad, Hercules, CA,
USA).
In vitro ubiquitination assay and APC/C inhibitory assay
In vitro ubiquitination assay and APC/C inhibitory assay were
performed as previously described (Braunstein et al., 2007;
Reddy et al., 2007). Further details are provided in the
Supplementary Materials and Methods.
In vitro kinase assay
Aurora A or Aurora B kinase assay was performed according
to the manufacturer’s protocol (Cell Signaling Technology,
Beverly, MA, USA). Further details are provided in the
Supplementary Materials and Methods.
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